Are Small Adrenal Incidentalomas Solely a Radiological Finding?

Abstract

Objective: The criterium defining the threshold size of adrenal incidentaloma (AI) is a size greater than 1 cm diameter. However, data concerning AI≤1 cm in diameter is scant. The aim of this study was to evaluate the function of adrenal masses≤1 cm and to compare them with adrenal masses>1 cm.

Materials and Methods: The study included 130 consecutive patients with AI (38 and 92 AI at ≤ 1 cm and > 1 cm, respectively). The patients were evaluated according to demographic and hormonal characteristics.

Results: The prevalence of SCS was 5.3 and 12% in AI≤1 cm and > 1 cm diameter, respectively. Hyperaldosteronism was found only in patients with > 1 cm AI. Pheochromocytoma were not found in either group. Patients with > 1 cm AI had a higher prevalence of SCS and primary hyperaldosteronism than patients with ≤ 1 cm AI, but the difference was not significant. The prevalence of diabetes and hypertension was high both in non-functional AI with ≤ 1 cm and > 1 cm patients and showed no significant difference between the 2 groups.

Conclusion: Our study is the first to focus on the clinical and hormonal characteristics of patients with ≤ 1 cm AI. Those with AI≤1 cm harboured SCS, as was the case for AI>1 cm. Similar to AI>1 cm, non-functional AI≤1 cm also had a higher prevalence of diabetes and hypertension.

Key words

adrenal incidentaloma - subclinical Cushing’s syndrome - adrenal size

• References

• 1 Kloos RT, Gross MD, Francis IR et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460-484
• 2 Arnaldi G, Boscaro M. Adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab 2012; 26: 405-419
• 3 Nieman LK. Approach to the patient with an adrenal incidentaloma. J Clin Endocrinol Metab 2010; 95: 4106-4113
• 4 Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract Res Clin Endocrinol Metab 2012; 26: 69-82
• 5 Valli N, Catargi B, Ronci N et al. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal incidentalomas. Eur J Endocrinol 2001; 144: 401-408
• 6 Young Jr WF. Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 2000; 29: 159-185
• 7 Vassiliadi DA, Ntali G, Vicha E et al. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin Endocrinol (Oxf) 2011; 74: 438-444
• 8 Emral R, Uysal AR, Asik M et al. Prevalence of subclinical Cushing’s syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical and surgical outcomes. Endocr J 2003; 50: 399-408
• 9 Garrapa GG, Pantanetti P, Arnaldi G et al. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. J Clin Endocrinol Metab 2001; 86: 5301-5306
• 10 Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 11 Satman I, Omer B, Tutuncu Y et al. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28: 169-180
• 12 Funder JW, Carey RM, Fardella C et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281
• 13 Terzolo M, Stigliano A, Chiodini I et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-870
• 14 Omura M, Sasano H, Fujiwara T et al. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002; 51: 350-355
• 15 Nishikawa T, Omura M. Clinical characteristics of primary aldosteronism: its prevalence and comparative studies on various causes of primary aldosteronism in Yokohama Rosai Hospital. Biomed Pharmacother 2000; 54: 83-85
• 16 Barzon L, Sonino N, Fallo F et al. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273-285